Business
INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021
LA JOLLA, Calif, March 08, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused
About this update from Inmune Bio Inc.
[{"type":"text","content":"LA JOLLA, Calif, March 08, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that its management team is scheduled to participate in two upcoming virtual investor conferences in March 2021. 33rd Annual Roth Virtual ConferencePanel Discussion: Therapeutics Against SARS-CoV-2 – Viral Variants Will Not Fade AwayPanel Date: Monday, March 15, 2021 Panel Time: 12:00 PM Eastern TimeInterested parties may register for the panel here Oppenheimer 31st Annual Healthcare ConferencePresentation Date: Tuesday, March 16, 2021Presentation Time: 1:10 PM Eastern TimeInterested parties may register for the panel here Please contact your representative at either Roth or Oppenheimer to schedule a virtual one-on-one meeting with INmune Bio during the respective conference. About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com. Information about Forward-Looking StatementsClinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking stat...